InvestorsHub Logo
icon url

H2R

11/22/19 10:55 AM

#4711 RE: hyperopia #4706

New SoS article after the Jefferies Healthcare Conference

Larry continues to be optimistic about the launch and market share for Xyosted and the EpiPen.

https://smithonstocks.com/antares-pharma-highlights-from-presentation-at-jefferies-healthcare-conference-atrs-buy-4-79/

Interesting info on his blog.

One basic takeaway:

Sales guidance for 2019 has been raised twice over the course of the year. Latest guidance for 2019 is $110 to $120 million. Sales in 2018 were $64 million.



Best of luck with your investments!